EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood pressure reduction and anti-inflammatory macrophage augmentation attenuate uterine immune dysregulation and inflammation in mice with salt-sensitive hypertension

Shobana Navaneethabalakrishnan iD, Bethany L Goodlett, Hannah L Smith, Alyssa Cardenas, Robert A Montalvo Ii, Gabriella C Peterson, Brett M Mitchell iD

Clinical Science · 10.12.2025 · 139 (23) · 1629-1642

DOI: 10.1042/cs20255879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, online erschienen am 10.12.2025. Verfasst von Shobana Navaneethabalakrishnan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physiology, Texas A&M College of Medicine, Bryan, Texas, 77807, U.S.A. Hauptthemen laut MEDLINE: Macrophages, Uterus, Hypertension, Blood Pressure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, American Heart Association, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Salt-sensitive hypertension (SSHTN) promotes systemic inflammation, pro-inflammatory immune cell infiltration, and end-organ damage, including in the kidneys and gonads. However, its impact on uterine immune cell populations remains unclear. We hypothesized that SSHTN alters immune cell homeostasis, induces inflammation, and promotes lymphangiogenesis in the uterus, and that these effects can be mitigated by pharmacological blood pressure (BP) reduction and anti-inflammatory macrophage augmentation. To test the hypothesis, female C57BL6/J mice were given nitro-L-arginine methyl ester hydrochloride (0.5 mg/ml) in drinking water for 2 weeks, followed by a 2-week washout period. Mice were then subjected to a 4% high-salt diet (SSHTN) for 3 weeks. Another group of mice received either hydralazine (HYD; 250 mg/l in drinking water), a vasodilator (SSHTN+HYD), or AVE0991 (AVE; 0.58 µmol/kg body weight/day), a nonpeptide Mas receptor agonist, through daily intraperitoneal injections (SSHTN+AVE). Control mice received tap water and a standard diet for the entire treatment period. Flow cytometry data revealed a significant decrease in total uterine CD45+ immune cells, along with an increase in tissue macrophages, in all SSHTN groups compared with the control group. SSHTN mice had increased uterine pro-inflammatory macrophages, dendritic cells, natural killer cells, and CD4+ pro-inflammatory T cells, all of which were mitigated by HYD and AVE treatments. SSHTN promoted uterine inflammation, lymphatic vessel expansion, and altered hormone receptor expression, which were mitigated by pharmacological intervention, highlighting their therapeutic potential in preserving uterine homeostasis and improving reproductive health in women with SSHTN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesUterusHypertensionBlood PressureInflammationAntihypertensive AgentsAnimalsFemaleMice, Inbred C57BLSodium Chloride, DietaryMiceHydralazineLymphangiogenesisDisease Models, AnimalNG-Nitroarginine Methyl Ester

Stichwörter der Autor:innen

hormone receptorshypertensionlymphaticsmacrophagesuterus

Substanzen

Sodium Chloride, DietaryHydralazineAntihypertensive AgentsNG-Nitroarginine Methyl Ester

Autor:innen und Institutionen

  • Department of Medical Physiology, Texas A&M College of Medicine, Bryan, Texas, 77807, U.S.A.

ORCID-Profile: Shobana Navaneethabalakrishnan, Brett M Mitchell

Förderung

  • NIDDK NIH HHS
  • American Heart Association
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Navaneethabalakrishnan, S., Goodlett, B. L., Smith, H. L., Cardenas, A., Montalvo Ii, R. A., Peterson, G. C., & Mitchell, B. M. (2025). Blood pressure reduction and anti-inflammatory macrophage augmentation attenuate uterine immune dysregulation and inflammation in mice with salt-sensitive hypertension. Clinical Science, 139(23), 1629-1642. https://doi.org/10.1042/cs20255879

Vancouver

Navaneethabalakrishnan S, Goodlett BL, Smith HL, Cardenas A, Montalvo Ii RA, Peterson GC, et al. Blood pressure reduction and anti-inflammatory macrophage augmentation attenuate uterine immune dysregulation and inflammation in mice with salt-sensitive hypertension. Clinical Science. 2025;139(23):1629-1642. doi:10.1042/cs20255879

BibTeX
@article{Navaneethabalakrishnan2025,
  author = {Navaneethabalakrishnan, Shobana and Goodlett, Bethany L and Smith, Hannah L and Cardenas, Alyssa and Montalvo Ii, Robert A and Peterson, Gabriella C and Mitchell, Brett M},
  title = {Blood pressure reduction and anti-inflammatory macrophage augmentation attenuate uterine immune dysregulation and inflammation in mice with salt-sensitive hypertension},
  journal = {Clinical Science},
  year = {2025},
  volume = {139},
  number = {23},
  pages = {1629--1642},
  doi = {10.1042/cs20255879}
}
Kostenlos starten →